Arontier
Seoul, KR · 2 known investors
Arontier is a company that applies artificial intelligence to drug discovery, using proprietary technology and data to develop treatments for incurable and rare diseases. Founded in 2017, it collaborates with companies, experts, and scholars on new medicines and genetic editing.
Also known as ì•„ë¡ í‹°ì–´
Investors · 2
Company profile
researched Aug 2026Arontier is a Seoul-headquartered artificial intelligence company working in precision medicine and drug discovery. Its stated drug design approach combines fundamental physics-based principles with machine learning to design antibodies, protein binders, peptidomimetics and small-molecule drugs. The company describes three main design areas: antibody design, using generative and language-model-based methods for CDR backbone design together with deimmunization and paratope-based functional antibody classification for epitope-specific design; protein and peptide binder design, using deep learning for generative protein backbone design, exploration of protein conformational space and prediction of protein-protein interactions, supported by molecular dynamics simulations; and small-molecule drug design, combining AI-driven exploration of protein conformational heterogeneity with generative design and medicinal chemistry expertise in a high-throughput virtual screening workflow.
The company positions itself as an AI-driven drug discovery start-up applying bioinformatics and pharmacogenomics to incurable and rare diseases. Its stated mission is to address the rising cost, low clinical success rate and low return on investment of conventional drug development by using AI to accelerate discovery. Alongside new medicine development, the company says it also works on genetic editing in collaboration with domestic and international companies, experts and academics. It has additional internal functions covering precision diagnosis, platform engineering and cancer-associated fibroblast (CAF) research.
Business model
Arontier develops AI-based drug discovery technology and has launched its own AI-based drug discovery service platform, working through projects and collaborations with companies, experts and academic researchers on new medicines and genetic editing.
Latest developments
Company news listings cite an AI platform for CAF-based eRNA target discovery presented at AACR (April 2026), an AI-based small-molecule design and synthesis service arrangement with Synthenta (March 2026), an in-house AI design platform reported to increase mRNA expression roughly tenfold (March 2026), expanded AI-based non-clinical evaluation work with Organoid Sciences (January 2026), a candidate-discovery workshop with K-MEDI hub (December 2025), and participation in a national project on next-generation ADC manufacturing technology (December 2025).
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Arontier describes itself as an AI-driven drug discovery start-up that has become an established participant in Korea's AI drug discovery field through project selections and collaborations since its 2017 founding.
Technology
The company's platform integrates physics-based modeling with machine learning across three design modalities. For antibodies it applies generative and language-model methods for exploratory CDR backbone design plus deimmunization and paratope-based functional classification. For protein and peptide binders it uses deep learning for generative protein backbone design, conformational space exploration and protein-protein interaction prediction, combined with molecular dynamics simulations. For small molecules it couples AI-based modeling of protein conformational heterogeneity with generative design and medicinal chemistry in a high-throughput virtual screening pipeline. The company also references work in bioinformatics, pharmacogenomics, precision diagnosis and cancer-associated fibroblast biology.
Go-to-market
The company works through collaborations and selected projects with domestic and international companies, experts and scholars, and offers an AI-based drug discovery service platform; it also presents its work at industry and scientific events.
Pharmaceutical and biotechnology organizations, research institutes and academic collaborators pursuing candidate discovery for incurable and rare diseases.
Geography
Headquartered at 15F, 241 Gangnam-daero, Seocho-gu, Seoul, Republic of Korea, with collaborations described as both domestic and international.
History
Arontier states it was established in November 2017. Since then it says it has been selected for a range of projects and collaborations in AI-driven drug discovery, and has more recently launched its own AI-based drug discovery service platform aimed at supporting treatments for incurable and rare diseases.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 5
launches, deals, and filingsCompany news listing reports Arontier unveiling an AI platform for cancer-associated fibroblast (CAF)-based eRNA target discovery at AACR.
Company news listing reports Arontier conducting AI-based small molecule design and synthesis services with Synthenta.
Company news listing reports Organoid Sciences and Arontier expanding AI-based non-clinical evaluation technology.
Company news listing reports Arontier joining a government-funded project to develop next-generation ADC manufacturing innovation technology.
Company news listing reports K-MEDI hub holding a new drug candidate discovery workshop with AI drug discovery firm Arontier.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Arontierarontier.co · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Arontier do?
- Seoul-based AI drug discovery company designing antibodies, protein/peptide binders and small molecules for precision medicine.
- Who are Arontier's investors?
- Arontier's investors include Kiwoom Investment, We Ventures.
- Where is Arontier headquartered?
- Arontier is headquartered in Seoul, KR.